Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. announced the completion of a placing and subscription agreement, resulting in the successful placement of 22,561,000 shares and raising approximately HK$1,553.39 million. The proceeds will be used for research and development, commercialization efforts, and general business operations, with a focus on advancing pipeline products and launching new medicines.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company is engaged in global research and development, particularly in mRNA technology and treatments for cancer and autoimmune diseases, with a market focus on launching new products and expanding its supply chain.
Average Trading Volume: 7,095,495
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.94B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.